Evaluating Risankizumab’s Long-Term Effects in Psoriasis Using Optical Coherence Tomography
Abstract Introduction Psoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. Ho...
Spremljeno u:
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Adis, Springer Healthcare
2026-01-01
|
| Serija: | Dermatology and Therapy |
| Teme: | |
| Online pristup: | https://doi.org/10.1007/s13555-025-01637-2 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|